Chronic graft-versus-host-disease (cGvHD) remains the leading cause of morbidity among
transplant recipients. The efficacy of second-line treatments varies widely based on many …

Allogeneic haematopoietic stem cell transplantation (alloHSCT) offers a potentially curative
therapy for patients suffering from diseases of the haematopoietic system but requires a high …

Acute and chronic graft-versus-host disease (GvHD) is a major cause of morbidity and
mortality in patients who undergo allogeneic haematopoietic cell transplantation (HCT) and …

Background Graft-versus-host disease (GVHD) is the major cause of short-and long-term
morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Treatment …

PURPOSE Shared decision making (SDM) is essential to empower patients with blood
cancers to make goal-concordant decisions about allogeneic hematopoietic cell …

Background: More than half the long-term survivors of allogeneic hematopoietic cell
transplantation develop chronic graft-versus-host disease (GVHD), a debilitating …

Patients facing situations with significant unpredictability are met with challenges to
expectation formation and preparation. One such context with unpredictable clinical …

Importance Cutaneous chronic graft-vs-host disease (GVHD) is independently associated
with morbidity and mortality after allogeneic hematopoietic cell transplant. However, the …

Purpose Despite a haematopoietic stem cell transplant (HSCT) being a potentially curative
treatment option for malignant and non-malignant disorders, patients may develop complex …

Background Prolonged periods of immunosuppression during hematopoietic stem cell
transplant (HSCT) can result in serious infectious complications and contribute to transplant …